Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

September 23, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten

It’s Friday (and print day for the Pharmafocus October edition!) and its been a pretty explosive week, from new and …
News
alzheimers_brain

Alzheimer’s drug failure sends Lundbeck’s shares crashing

September 23, 2016 Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings

Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …
News
shutterstock_232245868

Novartis’ Zykadia smashes Phase III target for lung cancer

September 23, 2016 Medical Communications, Research and Development Novartis, lung cancer, zykadia

Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating …
News
shutterstock_359806121

DNA damage response biotech launches with £25m funding

September 22, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, dna damage response, funding

Cambridge-based Artios Pharma has officially launched after raising £25 million in series A financing from US and European life science …
News
un_assembly

193 countries sign UN declaration to fight drug-resistant infection

September 22, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jeremy Hunt, UN, drug-resistant infection

A historic UN declaration to fight drug-resistant infection across the globe has been signed by 193 countries at the United …
News
gilead-sciences

Gilead terminates Phase II/III study for ulcerative colitis antibody

September 22, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, ulcerative colitis

Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative …
News

AZ withdraws European filing for ovarian cancer therapy

September 22, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, cediranib, ovarian cancer

AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …
News
heather_bresch

EpiPen CEO appears before US lawmakers to defend “sickening” price hikes

September 22, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Heather Bresch, Mylan, epipen

Disgraced Mylan CEO Heather Bresch (pictured) has appeared before US lawmakers to defend the company’s now infamous and much-maligned inflation …
News
2363

GSK appoints Emma Walmsley as first female CEO

September 21, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, appointment

GlaxoSmithKline, the UK’s biggest drugs company, has appointed Emma Walmsley as its new CEO. Walmsley will step into the vacancy …
Appointment
shutterstock_168864905

GE Healthcare doubles India investment

September 21, 2016 Manufacturing and Production, Research and Development, Sales and Marketing GE Healthcare, India

UK firm GE Healthcare is set to double its investment in India as it aims for revenues of £750 million …
News
amgen_hq

Positive Phase III results for Amgen’s Repatha for coronary artery disease

September 21, 2016 Research and Development Amgen, Phase III trial, Repatha

Amgen has announced that its monoclonal antibody Repatha (evolocumab) achieved positive Phase III results for the treatment of coronary artery …
News
shutterstock_273326141

Teva and Regeneron team up for $2.6 billion pain treatment development

September 21, 2016 Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis

Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …
News
microsoft-80658_1280

AstraZeneca and Microsoft to develop ‘drag and drop’ cancer simulation

September 21, 2016 Medical Communications, Research and Development AstraZeneca, Digital Pharma Guide, Microsoft

AstraZeneca has entered into a partnership with tech giant Microsoft to develop a new computerised modelling system which promises to …
News
allergan

Allergan expands NASH portfolio with $1.7 billion in acquisitions

September 21, 2016 Research and Development, Sales and Marketing Akarna Therapeutics, Allergan, Tobira Therapeutics, acqusition, nash

Allergan has gone on a spending spree this week, snapping up clinical-stage biotech Tobira Therapeutics and privately-held Akarna Therapeutics for …
News
a_scientist_at_work_at_sanofis_immunology_laboratory_in_thailand

Sanofi reveals promising data for relapsing remitting MS treatment

September 20, 2016 Manufacturing and Production, Research and Development RRMS, Sanofi, relapsing remitting multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi Genzyme, the speciality care global business unit of the French pharma firm announced six-year investigational data on Lemtrada (alemtuzumab) …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025